Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.
[en] Strategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry‐based matched‐pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete remission (CR) and controls were pair‐matched for age, diagnosis, cytogenetics, stage, donor, gender, conditioning and T‐cell depletion. Eighty‐nine pairs were identified (median follow‐up: 6.9 years). Within the entire cohort, no difference was observed. However, among patients with high‐risk acute myeloid leukaemia (AML) (unfavourable cytogenetics and/or transplanted beyond first CR), proDLI recipients had improved overall survival (69.8% vs. 40.2% in controls, P = 0.027). ProDLI has moderate efficacy, but can contribute to improved outcome in high‐risk AML.
Disciplines :
Hematology
Author, co-author :
Schmid, Christoph
Labopin, Myriam
Schaap, Nicolaas
Veelken, Hendrik
Schleuning, Michael
Stadler, Michael
Finke, Juergen
Hurst, Erin
BARON, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'hématologie clinique
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT.
Bejanyan, N., Weisdorf, D.J., Logan, B.R., Wang, H.L., Devine, S.M., de Lima, M., Bunjes, D.W. & Zhang, M.J. (2015) Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biology of Blood and Marrow Transplantation, 21, 454–459.
Bellucci, R., Alyea, E.P., Weller, E., Chillemi, A., Hochberg, E., Wu, C.J., Canning, C., Schlossman, R., Soiffer, R.J., Anderson, K.C. & Ritz, J. (2002) Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood, 99, 4610–4617.
Dominietto, A., Pozzi, S., Miglino, M., Albarracin, F., Piaggio, G., Bertolotti, F., Grasso, R., Zupo, S., Raiola, A.M., Gobbi, M., Frassoni, F. & Bacigalupo, A. (2007) Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood, 109, 5063–5064.
Eefting, M., Halkes, C.J., de Wreede, L.C., van Pelt, C.M., Kersting, S., Marijt, E.W., von dem Borne, P.A., Willemze, R., Veelken, H. & Falkenburg, J.H. (2014) Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplantation, 49, 287–291.
Goodyear, O., Agathanggelou, A., Novitzky-Basso, I., Siddique, S., McSkeane, T., Ryan, G., Vyas, P., Cavenagh, J., Stankovic, T., Moss, P. & Craddock, C. (2010) Induction of a CD8 + T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood, 116, 1908–1918.
Jedlickova, Z., Schmid, C., Koenecke, C., Hertenstein, B., Baurmann, H., Schwerdtfeger, R., Tischer, J., Kolb, H.J. & Schleuning, M. (2016) Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplantation, 51, 663–667.
Krishnamurthy, P., Potter, V.T., Barber, L.D., Kulasekararaj, A.G., Lim, Z.Y., Pearce, R.M., de Lavallade, H., Kenyon, M., Ireland, R.M., Marsh, J.C., Devereux, S., Pagliuca, A. & Mufti, G.J. (2013) Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biology of Blood and Marrow Transplantation, 19, 562–568.
Lee, C.J., Savani, B.N., Mohty, M., Gorin, N.C., Labopin, M., Ruggeri, A., Schmid, C., Baron, F., Esteve, J., Giebel, S., Ciceri, F. & Nagler, A. (2018) Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. [Epub ahead of print]. https://doi.org/10.1038/s41409-018-0286-2.
Mathew, N.R., Baumgartner, F., Braun, L., O'Sullivan, D., Thomas, S., Waterhouse, M., Müller, T.A., Hanke, K., Taromi, S., Apostolova, P., Illert, A.L., Melchinger, W., Duquesne, S., Schmitt-Graeff, A., Osswald, L., Yan, K.L., Weber, A., Tugues, S., Spath, S., Pfeifer, D., Follo, M., Claus, R., Lübbert, M., Rummelt, C., Bertz, H., Wäsch, R., Haag, J., Schmidts, A., Schultheiss, M., Bettinger, D., Thimme, R., Ullrich, E., Tanriver, Y., Vuong, G.L., Arnold, R., Hemmati, P., Wolf, D., Ditschkowski, M., Jilg, C., Wilhelm, K., Leiber, C., Gerull, S., Halter, J., Lengerke, C., Pabst, T., Schroeder, T., Kobbe, G., Rösler, W., Doostkam, S., Meckel, S., Stabla, K., Metzelder, S.K., Halbach, S., Brummer, T., Hu, Z., Dengjel, J., Hackanson, B., Schmid, C., Holtick, U., Scheid, C., Spyridonidis, A., Stölzel, F., Ordemann, R., Müller, L.P., Sicre-de-Fontbrune, F., Ihorst, G., Kuball, J., Ehlert, J.E., Feger, D., Wagner, E.M., Cahn, J.Y., Schnell, J., Kuchenbauer, F., Bunjes, D., Chakraverty, R., Richardson, S., Gill, S., Kröger, N., Ayuk, F., Vago, L., Ciceri, F., Müller, A.M., Kondo, T., Teshima, T., Klaeger, S., Kuster, B., Kim, D.D.H., Weisdorf, D., van der Velden, W., Dörfel, D., Bethge, W., Hilgendorf, I., Hochhaus, A., Andrieux, G., Börries, M., Busch, H., Magenau, J., Reddy, P., Labopin, M., Antin, J.H., Henden, A.S., Hill, G.R., Kennedy, G.A., Bar, M., Sarma, A., McLornan, D., Mufti, G., Oran, B., Rezvani, K., Shah, O., Shah, O., Negrin, R.S., Nagler, A., Prinz, M., Burchert, A., Neubauer, A., Beelen, D., Mackensen, A., von Bubnoff, N., Herr, W., Becher, B., Socié, G., Caligiuri, M.A., Ruggiero, E., Bonini, C., Häcker, G., Duyster, J., Finke, J., Pearce, E., Blazar, B.R. & Zeiser, R. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 24, 282–291.
Reddy, P., Maeda, Y., Liu, C., Krijanovski, O.I., Korngold, R. & Ferrara, J.L. (2005) A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nature Medicine, 11, 1244–1249.
Schmid, C., Labopin, L., Veelken, H., Schaap, N., Schleuning, M., Stadler, M.J., Finke, J., Beguin, Y., Collin, M., Ljungman, P., Bug, G., Blaise, D., Tischer, J., Bloor, A., Afanasyev, B., Giebel, S., Gorin, N., Esteve, J., Ciceri, F., Savani, B., Baronn, F., Mailhol, A., Nagler, A. & Mohty, M. (2015) Efficacy, safety and long term results of prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia: a registry-based evaluation on 343 patients by the acute leukemia working party of EBMT. Blood, 126, 863.
Therneau, T., Grambsch, P. & Pankratz, V.S. (2003) Penalized survival models and frailty. Journal of Computational and Graphical Statistics, 12, 156–175.
Wang, Y., Liu, D.H., Fan, Z.P., Sun, J., Wu, X.J., Ma, X., Xu, L.P., Liu, K.Y., Liu, Q.F., Wu, D.P. & Huang, X.J. (2012a) Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clinical Transplantation, 26, 635–643.
Wang, Y., Liu, D.H., Xu, L.P., Liu, K.Y., Chen, H., Zhang, X.H., Chen, Y.H., Han, W., Wang, F.R., Wang, J.Z., Yan, C.H. & Huang, X.J. (2012b) Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplantation, 47, 1099–1040.
West, A.C. & Johnstone, R.W. (2014) New and emerging HDAC inhibitors for cancer treatment. The Journal of Clinical Investigation, 124, 30–39.
